MedWatch

Potential conflict of interests forces board member out of Novo

This week, Novo Nordisk has said goodbye to one of its board members, Mary Szela. The reason is a potential conflict of interests related to Szela’s position as CEO of a US-based biotech company, which has moved into an area that Novo Nordisk also focuses on.

Foto: Novo Nordisk/ PR

The now former board member in Novo Nordisk, Mary Szela leaves the company with immediate effect. This was stated in a press release earlier this week.

“The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest,” writes Novo Nordisk.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier